Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla...
Related Questions
Will the management address any recent analyst concerns or stock volatility?
Will there be any updates on the pipeline, especially the late-stage programs like for Parkinson's disease or Tou Tou?
What are the anticipated cash flow impacts from recent acquisitions or collaborations?
How does the company foresee its market share evolving in the neuropsychiatric and oncology segments?
What key financial metrics will the management highlight during the conference?
Are there any upcoming FDA decisions or regulatory milestones discussed?
Is there any discussion about future capital raises or debt refinancing?
What are the expectations for operating expenses and R&D spend going forward?
Will the company provide guidance on revenue growth for the next fiscal year?
Will there be any updates on partnerships or licensing deals with other pharma companies?
How does the current valuation compare to peers within the biotech sector after the conference?